MSB Trading - 2020, page-7748

Thanks Cato. Funny, the one thing you don't mention in that list of concerns (basically competition from other therapies/vaccines and potential suppply issues) is the possibility of any one or more of the three phase 3 trials failing. That would almost certainly be the first concern of any rational investor. On that matter, just about everyone here has made their own risk/reward assessment. Anyway, your views on investing basics seem to change from month to month which makes it difficult to stick to any long term strategy. Like most here I think that on a risk reward basis MSB is presenting investors with what may prove to be the opportunity of a lifetime.